Medical Industry Feature

00:00:00

Neuroplasticity: A Potential Target for the Treatment...

Medical Industry Feature ·

2023/10/10

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Madhukar H. Trivedi, MD The brain is constantly changing as a result of experience, stress, emotional processing, learning, and memory.1 And neuroplasticity adds another layer to these approaches by focusing on what’s actually changing in the brain.2 Tune in with Dr. Charles Turck as he speaks with Dr. Madhukar Trivedi, Founding Director of the Center for Depression Research and Clinical Care and Chief of the Division of Mood

en

00:00:00

Neuroplasticity: A Potential Target for the Treatment...

Medical Industry Feature ·

2023/10/10

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Madhukar H. Trivedi, MD The brain is constantly changing as a result of experience, stress, emotional processing, learning, and memory.1 And neuroplasticity adds another layer to these approaches by focusing on what’s actually changing in the brain.2 Tune in with Dr. Charles Turck as he speaks with Dr. Madhukar Trivedi, Founding Director of the Center for Depression Research and Clinical Care and Chief of the Division of Mood

en

00:00:00

Addressing Hesitancy on Biosimilars: From Development...

Medical Industry Feature ·

2023/09/14

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jerome Goldschmidt, MD Despite the potential benefits of biosimilars, such as decreased costs for patients, healthcare systems, and payers,1,2 their uptake in U.S. clinical practice has lagged behind that of the E.U.2 That’s why Dr. Jerome Goldschmidt joins Dr. Charles Turck to address common misconceptions surrounding biosimilars and examine key points in their development, manufacturing, and approval process. Dr. Goldschmidt is a

en

00:00:00

From Monoamines to Neurocircuits: Our Evolving...

Medical Industry Feature ·

2023/08/30

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joseph F. Goldberg, MD Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City

en

00:00:00

From Heterogeneity Comes New Insights: Exploring the...

Medical Industry Feature ·

2023/08/29

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathan Silverberg, MD, PhD, MPH Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr

en

00:00:00

A Case for 4F-PCC: Mortality & Safety Data vs. Plasma

Medical Industry Feature ·

2023/07/28

Host: Jennifer Caudle, DO Guest: Michelle Kincaid, MD The largest study to date on 4F-PCC was conducted as an FDA postmarketing requirement in partnership between Kaiser Permanente and CSL Behring. The purpose of this long-term study was to compare the 45-day risk of thromboembolic events and all-cause mortality in adults with warfarin-associated major bleeding after treatment with KCENTRA®, Prothrombin Complex Concentrate (Human), or plasma. Take a deep dive into the data with Dr

en

00:00:00

Vaccine Viewpoint: Looking at Cell-Based Technology...

Medical Industry Feature ·

2023/07/24

Host: Jennifer Caudle, DO Guest: Ravi Jhaveri, MD Influenza vaccines have prevented between 39,000 and 105,000 hospitalizations and between 3,700 and 9,800 deaths each year over the last 10 years in the United States alone.1 But many challenges still exist in the traditional egg-based influenza vaccine manufacturing process. To explore how cell-based vaccines, an option that uses an alternative manufacturing approach, could help address those challenges and the overall influenza

en

00:00:00

Vaccine Viewpoint: Looking at Cell-Based Technology...

Medical Industry Feature ·

2023/07/24

Host: Jennifer Caudle, DO Guest: Ravi Jhaveri, MD Influenza vaccines have prevented between 39,000 and 105,000 hospitalizations and between 3,700 and 9,800 deaths each year over the last 10 years in the United States alone.1 But many challenges still exist in the traditional egg-based influenza vaccine manufacturing process. To explore how cell-based vaccines, an option that uses an alternative manufacturing approach, could help address those challenges and the overall influenza

en

00:00:00

Inflammation Biosimilars: Examining the Totality of...

Medical Industry Feature ·

2023/07/17

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gil Melmed, MD, MS The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed,

en

00:00:00

Enhancing Your Aesthetic Skillset: A New Training and...

Medical Industry Feature ·

2023/07/07

Host: Jennifer Caudle, DO Guest: Jeran Wadlow Guest: Josh Elmassian, MBA Allergan Medical Institute® has taken a personalized approach to training HCPs in medical aesthetics with the launch of AMI Online. Discover multiple online courses spanning the Allergan Aesthetics portfolio, including content on JUVÉDERM® VOLUX® XC. Experience how AMI Online’s evidence-based and progressive training curricula can educate and empower the aesthetics community. Join Dr Jennifer Caudle as she

en

00:00:00

Understanding Lp(a): Clinical Implications of an...

Medical Industry Feature ·

2023/06/22

Guest: Santica Marcovina, PhD, ScD Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

en

00:00:00

The ASCVD Journey With Lp(a): An ApoB-Family Lipoprotein

Medical Industry Feature ·

2023/06/22

Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

en

00:00:00

Letters from the Heart: People Should Know About Lp(a)

Medical Industry Feature ·

2023/06/22

It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

en

00:00:00

Understanding Lp(a): Clinical Implications of an...

Medical Industry Feature ·

2023/06/22

Guest: Santica Marcovina, PhD, ScD Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

en

00:00:00

Letters from the Heart: People Should Know About Lp(a)

Medical Industry Feature ·

2023/06/22

It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

en

00:00:00

The ASCVD Journey With Lp(a): An ApoB-Family Lipoprotein

Medical Industry Feature ·

2023/06/22

Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

en

00:00:00

Inherited Retinal Diseases, Genetic Testing, and What...

Medical Industry Feature ·

2023/06/21

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Mark Pennesi, MD, PhD Approximately 165,700 people in the United States are affected by inherited retinal diseases (IRDs) and treatment options for these conditions are limited. So what role does genetic testing play in the patient journey of people living with IRDs? Join Dr. Charles Turck as he dives into this topic with Dr. Mark Pennesi, Professor of Ophthalmology and an IRD specialist affiliated with the Casey Eye Institute at the

en

00:00:00

Future Imaging Modalities in Spondyloarthritis

Medical Industry Feature ·

2023/05/18

Host: Ethan Craig, MD, MHS Guest: Walter Maksymowych, MB ChB, FRCP(C), FACP Appealing treatment options for patients with SpA might be right around the corner. So why do we need further imaging modalities and what do they have to offer? To give us a peek into the future, Dr. Ethan Craig is joined by Dr. Maksymowych, Professor of Medicine at the University of Alberta and Chief Medical Officer of CARE Arthritis. Dr. Craig and Dr. Bakewell are Novartis Consultants. 269162 03/23

en

00:00:00

The Role of Imaging in Determining Treatment...

Medical Industry Feature ·

2023/05/04

Host: Ethan Craig, MD, MHS Guest: Catherine J. Bakewell, MD Disease activity in patients with spondyloarthritis (SpA) may be challenging to assess. So when should ultrasound and MRI be used to support clinical assessment? To provide us with more insights into this topic, Dr. Ethan Craig is joined by Dr. Catherine Bakewell, Rheumatologist at Intermountain Healthcare in Salt Lake City, Utah. Dr. Craig and Dr. Bakewell are Novartis Consultants. 269162 03/23

en

00:00:00

A Changing Paradigm for Cancer Screening: Exploring...

Medical Industry Feature ·

2023/04/24

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr

en

All Episodes

Similar Podcasts

Cienciaes.com

cienciaes.com

天方烨谈

基因频道

汪诘：科学有故事（主打）

科学有故事

النشرة العلمية

مونت كارلو الدولية / MCD

Ciência

RFI Português